RecruitingPhase 2NCT03297606

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial


Sponsor

Canadian Cancer Trials Group

Enrollment

720 participants

Start Date

Mar 23, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Canadian study tests whether matching advanced cancer patients to targeted drugs based on the specific genetic changes in their tumors leads to better outcomes than standard treatment. **You may be eligible if...** - You are 18 or older with an advanced solid tumor (not a primary brain tumor), multiple myeloma, or a type of non-Hodgkin lymphoma that cannot be cured - Standard treatments are no longer working for you - Your tumor tissue is available for genetic testing - You have adequate organ function and are well enough to participate **You may NOT be eligible if...** - You have a primary brain tumor - You have certain types of leukemia (CLL, SLL, or HCL) - You are not well enough to tolerate therapy (poor performance status) - You cannot provide tumor tissue for testing Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOlaparib

300mg taken twice daily

DRUGDasatinib

100mg administered orally once daily

DRUGNivolumab plus Ipilimumab

* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

DRUGAxitinib

5mg orally twice daily

DRUGBosutinib

500mg orally once daily

DRUGCrizotinib

250mg orally twice daily

DRUGPalbociclib

125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

DRUGSunitinib

50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

DRUGTemsirolimus

25mg infused over a 30-60 minute period once a week

DRUGErlotinib

150mg orally, once daily

DRUGTrastuzumab plus Pertuzumab

Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

DRUGVemurafenib plus Cobimetinib

Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

DRUGVismodegib

150mg taken orally, once daily

DRUGTucatinib

300mg taken orally, twice daily


Locations(10)

Cross Cancer Institute

Edmonton, Alberta, Canada

BCCA - Kelowna

Kelowna, British Columbia, Canada

BCCA - Vancouver

Vancouver, British Columbia, Canada

Kingston Health Sciences Centre

Kingston, Ontario, Canada

London Health Sciences Centre Research Inc.

London, Ontario, Canada

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

University Health Network

Toronto, Ontario, Canada

The Jewish General Hospital

Montreal, Quebec, Canada

Allan Blair Cancer Centre

Regina, Saskatchewan, Canada

Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03297606


Related Trials